In vitro amoebicidal activity of a ceragenin, cationic steroid antibiotic-13, against Acanthamoeba castellanii and its cytotoxic potential

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 1, 2011, Pages 1-5

  Polat, Zubeyde Akin ^a   Savage, Paul B ^b   Genberg, Carl ^c  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Brigham Young University   (United States)

^c Ceragenix Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CATIONIC STEROID ANTIBIOTIC 13; CONTACT LENS SOLUTION; PHOSPHATE BUFFERED SALINE; STEROID; UNCLASSIFIED DRUG;

ACANTHAMOEBA CASTELLANII; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; IN VITRO STUDY; MOUSE; NONHUMAN; TROPHOZOITE;

ACANTHAMOEBA CASTELLANII; AMEBICIDES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNODIFFUSION; OSMOLAR CONCENTRATION; STEROIDS; TIME FACTORS; TOXICITY TESTS; TROPHOZOITES;

EID: 79951987452     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0041     Document Type: Article

References (38)

1. Clarke, D.W., and Niederkorn, J.Y. The pathophysiology of Acanthamoeba keratitis. Trends. Parasitol. 22:175-180, 2006.
2. Kumar, R., and Lloyd, D. Recent advances in the treatment of Acanthamoeba keratitis. Clin. Infect. Dis. 35:434-441, 2002.
3. Marciano-Cabral, F.R., Puffenbarger, R., and Cabral, G.A. The increasing importance of Acanthamoeba infections. J. Eukaryot. Microbiol. 47:29-36, 2000.
4. McCulley, J.P., Alizadeh H., and Niederkorn, J.Y. The diagnosis and management of Acanthamoeba keratitis. CLAO J. 26:47051, 2000.
5. Radford, C.F., Minassian, D.C., and Dart, J.K. Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors. Br. J. Ophthalmol. 86:536-542, 2002.
6. Stehr-Green, J.K., Bailey, T.M., and Visversvara, G.S. The epidemiology of Acanthamoeba keratitis in the United States. Am. J. Ophthalmol. 107:331-336, 1989.
7. Moore, M.B., McCulley, J.P., Newton, C., et al. Acanthamoeba keratitis. A growing problem in soft and hard contact lens wearers. Ophthalmology 94:1654-1661, 1987.
8. Moore, M.B., McCulley, J.P., Luckenbach, M., et al. Acanthamoeba keratitis associated with soft contact lenses. Am. J. Ophthalmol. 100:396-403, 1985.
9. Seal, D.V., Dalton, A., and Doris, D. Disinfection of contact lenses without tap water rinsing: is it effective? Eye 13:226-230, 1999.
10. Samples, J.R., Binder, P.S., Luibel, F.J., et al. Acanthamoeba keratitis possibly acquired from a hot tub. Arch. Ophthalmol. 102:707-710, 1984.
11. Cohen, E.J., Buchanan, H.W., Laughrea, P.A., et al. Diagnosis and management of Acanthamoeba keratitis. Am. J. Ophthalmol. 100:389-395, 1985.
12. Radford, C.F., Bacon, A.S., Dart, J.K.G., et al. Risk factors for Acanthamoeba keratitis in contact lens users: a case control study. BMJ 10:1567-1570, 1995.
13. Radford, C.F., Lehmann, O.J., and Dart, J.K.G. Acanthamoeba keratitis: multi-centre survey in England 1992-1996. Br. J. Ophthalmol. 82:1387-1392, 1998.
14. Bottene, E., Madayag, R.M., and Qureshi, M.N. Acanthamoeba keratitis: synergy between amebic and bacterial cocontaminants in contact lens care systems as a prelude to infection. J. Clin. Microbiol. 30:2447-2450, 1992.
15. Gray, T.B., Cursons, R.T., Sherwan, J.F., et al. Acanthamoeba, bacterial, and fungal contamination of contact lens storage cases. Br. J. Ophthalmol. 79:601-605, 1995.
16. Stevenson, R.W.W., and Seal, D.V. Has the introduction of multi-purpose solutions contributed to a reduction in Acanthamoeba keratitis in contact lens wearers?: a review. Contact Lens Anterior Eye 21:89-92, 1998. (Pubitemid 128535744)
17. Savage, P.B., Li, C., Taotafa, U., et al. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol. Lett. 217:1-7, 2002.
18. Boman, H.G. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 254:197-215, 2003.
19. Bucki, R., Pastore, J.J., Randhawa, P., et al. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob. Agents. Chemother. 48:1526-1533, 2004.
20. Jenssen, H., Hamill, P., Hancock, R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511, 2006.
21. Zanetti, M., Gennaro, R., Scocchi, M., et al. Structure and biology of cathelicidins. Adv. Exp. Med. Biol., 479: 203-218, 2000.
22. Ding, B., Guan, Q., Walsh, J.P., et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J. Med. Chem. 45:663-669, 2002.
23. Guan, Q, Li, C., Schmidt, E.J., et al. Preparation and characterization of cholic acid-derived antimicrobial agents with controlled stabilities. Org. Lett. 2:2837-2840, 2000.
24. Li, C., Peters, A.S., Meredith, E.L., et al. Design and synthesis of potent sensitizers of Gram-negative bacteria based on a cholic acid scaffolding. J. Am. Chem. Soc. 120:2961-2962, 1998.
25. Li, C., Driscoll, C.D., Budge, C.D., et al. Incremental conversion of outer-membrane permeabilizers into potent antibiotics for Gram-negative bacteria. J. Am. Chem. Soc. 121:931-940, 1999.
26. Walochnik, J., Obwaller, A., and Aspock, H. Correlations between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. Appl. Environ. Microbiol. 66:4408-4413, 2000.
27. Schuster, F.L. Cultivation of pathogenic and opportunistic free-living amebas. Clin. Microbiol., 15:342-354, 2002.
28. International Standard ISO 10993-5. Biological Evaluation of Medical Devices. Part 5: Tests for In Vitro Cytotoxicity. Geneva: International Organization for Standardization, 1999.
29. Duguid, I.G., Dart, J.K., Morlet, N., et al. Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology 104:1587-1592, 1997. (Pubitemid 28053455)
30. Meisler, D.M., and Rutherford, I. Acanthamoeba and disinfection of soft contac lenses. Rev. Infect. Dis. 13:410-412, 1991.
31. Russell, D.A., Furr, J.R., and Maillard, J.Y. Microbial susceptibility and resistance to biocides. Am. Soc. Microbiol. News 63:491-487, 1996.
32. Niszl, I.A., and Markus, M.B. Anti-Acanthamoeba activity of contact lens solutions. Br. J. Ophthalmol. 82:1033-1038, 1998.
33. Silvany, R.E., Dougherty, J.M., McCulley, J.P., et al. The effect of currently available contact lens disinfection systems on Acanthamoeba castellanii and Acanthamoeba polyphaga. Ophthalmology 97:286-290, 1990. (Pubitemid 20087973)
34. Larkin, D.F.P., Kilvington, S., and Easty, D.L. Contamination of contact lens storage cases by Acanthamoeba and bacteria. Br. J. Ophthalmol. 74:133-135, 1990.
35. Epand, R.M., Epand, R.F., and Savage, P.B. Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect. 21:307-311, 2008.
36. Savage, P.B., Michaelis, D., Orsak, T., et al. Thin film containing a cationic steroid antibiotic displays bacteridical activity. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. F-1235, 2005.
37. Savage, P.B., Chambers, H.F., Genberg, C., et al. Activity of a novel cationic steroid antimicrobial (CSA-13) argeting aerobic and facultative gram-negative bacilli, gram-positive anaerobes and select agent. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. F-1231, 2005.
38. Ritterband, D., Shah M., Crook, M.B., et al. In vitro activity of a ceragenin, CSA-13, against gram-positive ocular clinical isolates. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. F-1868, 2005.